Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17265
Abstract: Can therapy with clindamycin and rifampicin be safely continued long term beyond the recommended 10‐week course? read more here.
Keywords: clindamycin rifampicin; long term; clinical safety; term clinical ... See more keywords
Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side‐effects, improving patients’ compliance
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17423
Abstract: We read with great interest the article by Albrecht et al.1 regarding the long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis Suppurativa (HS). The authors discuss carefully whether Clindamycin and Rifampicin could be safely continued beyond… read more here.
Keywords: clindamycin rifampicin; long term; clinical safety; term clinical ... See more keywords
Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: a 6‐month prospective study
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19578
Abstract: treatment of Hidradenitis Suppurativa (HS) with systemic antibiotics are first line therapy according to European S1 guidelines [1]. Yet, despite being the most investigated antibiotic regimen in HS, the evidence-based literature on clindamycin and rifampicin… read more here.
Keywords: clindamycin rifampicin; therapy; hidradenitis suppurativa;